Interim financial statements

For the six-month period ended 30 June 2025



### CONTENTS

	Pages
General information	1
Report of management	2
Report on review of interim separate financial statements	3 - 4
Interim balance sheet	5 - 6
Interim income statement	7
Interim cash flow statement	8 - 9
Notes to the interim financial statements	10 - 32

### GENERAL INFORMATION

### THE COMPANY

No. 25 Central Pharmaceutical Joint Stock Company ("the Company") is a joint stock company established based on the equitization of a state-owned enterprise - No. 25 Central Pharmaceutical Enterprise according to Decision No. 5112/QĐ9-BYT dated 11 December 2006 by the Minister of Health. Accordingly, the Company was granted the Enterprise Registration Certificate ("ERC") No. 0300468511 by the Ho Chi Minh City Department of Planning and Investment for the first time on 19 June 2007 and the latest 19th amended ERC on 6 June 2024.

The Company's shares are traded on the unlisted public companies stock market ("UPCOM") with the stock code UPH issued by the Hanoi Stock Exchange on 29 December 2016.

The current principal activities of the Company are manufacturing pharmaceutical medicine, pharmaceutical chemistry, trading, services and real estates.

The head office of the Company is located at 448B, Nguyen Tat Thanh Street, Ward 18, District 4, Ho Chi Minh City, Vietnam (new address: 448B, Nguyen Tat Thanh Street, Xom Chieu Ward, District 4, Ho Chi Minh City, Vietnam).

### **BOARD OF DIRECTORS**

The members of the Board of Directors during the period and at the date of this report are:

Ms Pham Thi Xuan Huong Chairwoman
Ms Phuong Thanh Nhung Member
Mr Tran Tri Duc Member
Mr Ha Duc Cuong Member
Ms Ha Lan Anh Member

### **BOARD OF SUPERVISION**

The members of the Board of Supervision during the period and at the date of this report are:

Ms Huynh Thi Anh Thu Head
Ms Le Thi Anh Nguyet Member
Ms Nguyen Thu Thuy Member

### MANAGEMENT

The members of the management during the period and at the date of this report are:

Mr Nguyen Manh Hai General Director
Mr Ngo Tan Long Deputy General Director

### LEGAL REPRESENTATIVE

The legal representatives of the Company during the period and at the date of this report are:

Ms Pham Thi Xuan Huong Mr Nguyen Manh Hai

### **AUDITORS**

The auditor of the Company is Ernst & Young Vietnam Limited.

### REPORT OF THE MANAGEMENT

The management of No. 25 Central Pharmaceutical Joint Stock Company ("the Company") presents this report and the interim financial statements of the Company for the six-month period ended 30 June 2025.

### THE MANAGEMENT'S RESPONSIBILITY IN RESPECT OF THE INTERIM FINANCIAL STATEMENTS

The management is responsible for the interim financial statements which give a true and fair view of the interim financial position of the Company and of the interim results of its operations and its interim cash flows for the period. In preparing those interim financial statements, management is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- ▶ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the interim financial statements; and
- prepare the interim financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue its business.

The management is responsible for ensuring that proper accounting records are kept which disclose, with reasonable accuracy at any time, the interim financial position of the Company and for ensuring that the accounting records comply with the applied accounting system. It is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The management confirmed that it has complied with the above requirements in preparing the accompanying interim financial statements.

### STATEMENT BY THE MANAGEMENT

The management does hereby state that, in its opinion, the accompanying interim financial statements give a true and fair view of the interim financial position of the Company as at 30 June 2025, and of the interim results of its operations and its interim cash flows for the six-month period then ended in accordance with the Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the interim financial statements.

For and on behalf of the management.

CÔNG TY

Cổ PHẦN DƯỢC PHẨM

> Nguyen Manh Hai General Director

Ho Chi Minh City, Vietnam

14 August 2025

Ernst & Young Vietnam Limited 2 Hai Trieu Street, Sai Gon Ward Ho Chi Minh City, Vietnam Tel: +84 28 3824 5252 Email: eyhcmc@vn.ey.com Website (EN): ey.com/en\_vn Website (VN): ey.com/vi\_vn

Reference: 5493857/68684437/LR

### REPORT ON REVIEW OF INTERIM SEPARATE FINANCIAL STATEMENTS

To: The Shareholders of No. 25 Central Pharmaceutical Joint Stock Company

We have reviewed the accompanying interim financial statements of No. 25 Central Pharmaceutical Joint Stock Company ("the Company") as prepared on 14 August 2025 and set out on pages 5 to 32, which comprise the interim balance sheet as at 30 June 2025, the interim income statement, the interim cash flow statement for the six-month period then ended and the notes thereto.

### The management's responsibility

The Management is responsible for the preparation and presentation of these interim financial statements that give a true and fair view in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the interim financial statements, and for such internal control as management determines is necessary to enable the preparation and presentation of the interim financial statements that are free from material misstatement, whether due to fraud or error.

### Auditors' responsibility

Our responsibility is to express a conclusion on the interim financial statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagements No. 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of the interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





### Opinion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial statements do not give a true and fair view, in all material respects, of the interim financial position of the Company as at 30 June 2025, and of the interim results of its operations and its interim cash flows for the six-month period then ended in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the interim financial statements.

**Ernst & Young Vietnam Limited** 

Pham Thi Cam Tu

Deputy General Director

Audit Practicing Registration Certificate

No. 2266-2023-004-1

Ho Chi Minh City, Vietnam

14 August 2025

INTERIM BALANCE SHEET

as at 30 June 2025

				VIVD
Code	ASSETS	Notes	30 June 2025	31 December 2024
100	A. CURRENT ASSETS		277,802,761,208	292,739,521,837
<b>110</b> 111 112	<ul><li>I. Cash and cash equivalents</li><li>1. Cash</li><li>2. Cash equivalents</li></ul>	4	<b>9,781,585,099</b> 2,298,282,160 7,483,302,939	<b>28,283,162,460</b> 15,881,615,411 12,401,547,049
<b>120</b> 123	<ul><li>II. Short-term investment</li><li>1. Held- to-maturity investments</li></ul>	5	<b>40,000,000,000</b> 40,000,000,000	<b>38,000,000,000</b> 38,000,000,000
<b>130</b> 131	<ul><li>III. Current accounts receivable</li><li>1. Short-term trade receivables</li></ul>	6	<b>17,729,188,944</b> 34,320,506,820	<b>26,703,495,054</b> 41,267,169,521
132 136	<ol> <li>Short-term advances to suppliers</li> <li>Other short-term receivables</li> </ol>	7	1,115,174,887 4,407,126,000	1,112,434,887 6,437,509,409
137	<ol> <li>Provision for short-term doubtful receivables</li> </ol>	8	(22,113,618,763)	(22,113,618,763)
<b>140</b> 141	IV. Inventories 1. Inventories	9	<b>209,682,173,718</b> 212,130,940,293	<b>199,231,781,635</b> 201,768,051,752
149	<ol><li>Provision for obsolete inventories</li></ol>		(2,448,766,575)	(2,536,270,117)
			609,813,447	521,082,688
150	<ul><li>V. Other current assets</li><li>1. Short-term prepaid expenses</li></ul>		42,410,000	97,400,000
151 152	<ol> <li>Short-term prepaid expenses</li> <li>Deductible value-added tax</li> <li>Tax and other receivables</li> </ol>	10	397,606,027	146,265,258
153	from the State	10	169,797,420	
200	B. NON-CURRENT ASSETS		93,097,176,636	
<b>210</b> 216	<ul><li>I. Long-term receivable</li><li>1. Other long-term receivables</li></ul>	7	<b>3,771,660,200</b> 3,771,660,200	3,761,660,200
220 221 222 223	II. Fixed assets  1. Tangible fixed assets  Cost  Accumulated depreciation	11	18,688,697,615 18,688,697,615 109,629,094,69 (90,940,397,082	5   19,885,928,823 7   109,629,094,697
227 228 229	Intangible fixed assets     Cost     Accumulated amortisation		334,130,000 (334,130,000	(334,130,000)
<b>240</b> 242	III. Long-term asset in progress  1. Long-term work-in-process	12	<b>22,233,324,60</b> 22,233,324,60	8 21,237,108,032
<b>260</b> 261 262	<ul><li>IV. Other long-term assets</li><li>1. Long-term prepaid expenses</li><li>2. Deferred tax assets</li></ul>	13 21.3	<b>48,403,494,21</b> 47,851,931,08 551,563,12	48,562,134,538
270	TOTAL ASSETS		370,899,937,84	386,843,685,749

INTERIM BALANCE SHEET (continued) as at 30 June 2025

VND

Code	RE	SOURCES	Notes	30 June 2025	31 December 2024
300	C.	LIABILITIES		215,569,055,900	231,691,580,577
310 311 312 314 315 319 322	I.	<ol> <li>Current liabilities</li> <li>Short-term trade payables</li> <li>Short-term advances from customers</li> <li>Payables to employees</li> <li>Short-term accrued expenses</li> <li>Other short-term payables</li> <li>Bonus and welfare fund</li> </ol>	14.1 14.2 15	214,576,641,766 2,076,562,528 183,088,465,396 1,209,865,980 122,088,134 28,029,953,781 49,705,947	230,681,484,623 14,081,726,952 183,085,955,477 5,088,183,710 739,841,076 27,636,071,461 49,705,947
330 342 343 400	II.	Non-current liabilities  1. Long-term provisions  2. Scientific and technological development fund  OWNERS' EQUITY	3.11	<b>992,414,134</b> 959,997,500 32,416,634 <b>155,330,881,944</b>	<b>1,010,095,954</b> 959,997,500 50,098,454 <b>155,152,105,172</b>
410 411 411a 412 418 421 421a 421b	L	Owners' equity  1. Contributed charter capital  - Ordinary shares with voting rights  2. Share premium  3. Investment and development fund  4. Accumulated losses  - Accumulated losses by the end of prior period  - Undistributed earnings of the period	16.1	155,330,881,944 132,946,410,000 17,589,282,000 12,490,339,501 (7,695,149,557) (7,873,926,329) 178,776,772	155,152,105,172 132,946,410,000 17,589,282,000 12,490,339,501 (7,873,926,329) (10,944,239,776) 3,070,313,447
440	0,00 0000	OTAL LIABILITIES AND WNERS' EQUITY		370,899,937,844	386,843,685,749

Ho Chi Minh City, Vietnam

14 August 2025

Ngo Tan Long Preparer cum Deputy General Director

Nguyen Manh Hai General Director

Cổ PHẦN

### INTERIM INCOME STATEMENT for the six-month period ended 30 June 2025

VND

Code	ITEMS	Notes	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
01	Revenue from sale of goods and rendering of services	17.1	39,369,353,164	59,489,687,151
02	2. Deductions	17.1	-	(157,457)
10	Net revenue from sale of goods and rendering of services	17.1	39,369,353,164	59,489,529,694
11	Cost of goods sold and services rendered	18	(34,812,310,488)	(51,076,406,729)
20	5. Gross profit from sale of goods and rendering of services		4,557,042,676	8,413,122,965
21	6. Finance income	17.2	1,349,894,068	1,055,497,715
22	7. Finance expenses		(26,334,598)	(29,322,596)
25	8. Selling expenses	19	(404,335,569)	(761,493,111)
26	General and administrative expenses	19	(5,188,720,612)	(7,162,325,342)
30	10. Operating profit		287,545,965	1,515,479,631
32	11. Other expenses		(3,000,000)	(1,417,350)
40	12. Other loss		(3,000,000)	(1,417,350)
50	13. Accounting profit before tax		284,545,965	1,514,062,281
51	14. Current corporate income tax expense	21.1	-	-
52	15. Deferred tax expense	21.3	(105,769,193)	(1,287,000)
60	16. Net profit after corporate income tax	16.4	178,776,772	1,512,775,281
70	17. Basic earnings per share	16.4	13	114
71	18. Diluted earnings per share	16.4	13	114

Ho Chi Minh City, Vietnam

14 August 2025

DƯỢC PHẨM

Nguyen Manh Hai General Director

Ngo Tan Long Preparer cum Deputy General Director

ZA/ E/

### INTERIM CASH FLOW STATEMENT for the six-month period ended 30 June 2025

VND

Code	ITEMS	Notes	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
	I. CASH FLOWS FROM			
	OPERATING ACTIVITIES			
01	Profit before tax		284,545,965	1,514,062,281
	Adjustments for:			, , , ,
02	Depreciation of tangible fixed			
	assets	20	1,179,549,388	1,393,584,697
03	Provisions		(87,503,542)	(302,704,360)
04	Foreign exchange gains arising			
	from revaluation of monetary			
	accounts denominated in foreign		(10 519 012)	(17.260.715)
05	currency Profits from investing activities		(10,518,912) (1,178,932,701)	(17,369,715) (1,002,395,397)
05	Fronts from investing activities		(1,170,932,701)	(1,002,393,397)
08	Operating profit before changes in			
	working capital		187,140,198	1,585,177,506
09	Decrease (increase) in receivables		9,467,143,266	(5,685,980,782)
10	(Increase) decrease in inventories		(10,362,888,541)	814,202,312
11	(Decrease) increase in payables		(21,104,842,857)	12,526,075,124
12	Increase in prepaid expenses		(38,110,000)	36,250,000
17	Other cash outflows for operating activities			(8,500,000)
	activities		_	(0,300,000)
20	Net cash flows (used in) from			
	operating activities		(21,851,557,934)	9,267,224,160
	II. CASH FLOWS FROM INVESTING ACTIVITIES			
21	Purchase and construction of			
	fixed assets		(192,913,125)	-
23	Repayment of term deposits		(37,000,000,000)	(30,000,000,000)
24	Collections from term deposits		40,000,000,000	18,769,777,151
27	Interest received		532,374,786	946,827,026
30	Net cash flows from (used in)			
	investing activities		3,339,461,661	(10,283,395,823)

INTERIM CASH FLOW STATEMENT (continued) for the six-month period ended 30 June 2025

VND

Code	ITEMS	Notes	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
50	Net decrease in cash and cash equivalents for the period		(18,512,096,273)	(1,016,171,663)
60	Cash and cash equivalents at beginning of period		28,283,162,460	29,373,283,684
61	Impact of foreign exchange rate fluctuation		10,518,912	17,369,715
70	Cash and cash equivalents at end of period	4	9,781,585,099	28,374,481,736

Ho Chi Minh City, Vietnam

14 August 2025

Ngo Tan Long

Preparer cum Deputy General Director

Nguyen Manh Hai General Director

CÔNG TY CÔ PHẦN CỔ PHẨM DƯỢC PHẨM

15

I

NOTES TO THE INTERIM FINANCIAL STATEMENTS as at 30 June 2025 and for the six-month period then ended

### 1. CORPORATE INFORMATION

No. 25 Central Pharmaceutical Joint Stock Company ("the Company") is a joint stock company established based on the equitization of a state-owned enterprise - No. 25 Central Pharmaceutical Enterprise according to Decision No. 5112/QĐ9-BYT dated 11 December 2006 by the Minister of Health. Accordingly, the Company was granted the Enterprise Registration Certificate ("ERC") No. 0300468511 by the Ho Chi Minh City Department of Planning and Investment for the first time on 19 June 2007 and the latest 19th amended ERC on 6 June 2024.

The Company's shares are traded on the unlisted public companies stock market ("UPCOM") with the stock code UPH issued by the Hanoi Stock Exchange on 29 December 2016.

The current principal activities of the Company are manufacturing pharmaceutical medicine, pharmaceutical chemistry, trading, services and real estates.

The head office of the Company is located at 448B Nguyen Tat Thanh Street, Ward 18, Distric 4, Ho Chi Minh City, Vietnam (new address: 448B Nguyen Tat Thanh Street, Xom Chieu Ward, Ho Chi Minh City, Vietnam).

The number of the Company's employees as at 30 June 2025 was 111 (31 December 2024: 113 employees).

### 2. Basis of preparation

### 2.1 Accounting standards and system

The interim financial statements of the Company, expressed in Vietnam dong ("VND"), are prepared in accordance with Vietnamese Enterprise Accounting System, the Vietnamese Accounting Standard No. 27 - Interim Financial Reporting and other and Vietnamese Accounting Standards issued by the Ministry of Finance as per:

- Decision No. 149/2001/QD-BTC dated 31 December 2001 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 1);
- Decision No. 165/2002/QD-BTC dated 31 December 2002 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 2);
- Decision No. 234/2003/QD-BTC dated 30 December 2003 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 3);
- Decision No. 12/2005/QD-BTC dated 15 February 2005 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 4); and
- Decision No. 100/2005/QD-BTC dated 28 December 2005 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 5).

Accordingly, the accompanying interim financial statements, including their utilisation are not designed for those who are not informed about Vietnam's accounting principles, procedures and practices and furthermore are not intended to present the interim financial position and the interim results of operations and the interim cash flows of the Company in accordance with accounting principles and practices generally accepted in countries other than Vietnam.

### 2.2 Applied accounting documentation system

The Company's applied accounting documentation system is General Journal system.

### 2.3 Fiscal year

The Company's fiscal year applicable for the preparation of its financial statements starts on 1 January and ends on 31 December.

### 2.4 Accounting currency

The interim financial statements are prepared in VND which is also the Company's accounting currency.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### 3.1 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, cash at banks and short-term, highly liquid investments with an original maturity of less than three months that are readily convertible into known amounts of cash and subject to an insignificant risk of change in value.

### 3.2 Receivables

Receivables are presented in the interim balance sheet at the carrying amounts due from customers and other debtors, after provision for doubtful debts.

The provision for doubtful debts represents amounts of outstanding receivables at the interim balance sheet date which are doubtful of being recovered. Increases or decreases to the provision balance are recorded as general and administrative expenses in the interim income statement. When bad debts are determined as unrecoverable and accountant writes off those bad debts, the differences between the provision for doubtful receivables previously made and historical cost of receivables are included in the interim income statement.

### 3.3 Inventories

Inventories are measured at their historical costs. The cost of inventories comprises costs of purchase, costs of conversion (including raw materials, direct labor cost, other directly related cost, manufacturing general overheads allocated based on the normal operating capacity) incurred in bringing the inventories to their present location and condition.

In case the net realizable value is lower than the original price, it must be calculated according to the net realizable value.

Net realisable value ("NRV") represents the estimated selling price in the ordinary course of business less the estimated costs to complete and the estimated costs necessary to make the sale.

Perpetual method is used to record inventories, which are valued as follows:

Raw materials, tools and spare - cost of purchase on a first-in, first-out basis.

parts
Finished goods and work-in process - cost of finished goods on a specific identification basis.

### Provision for obsolete inventories

An inventory provision is made for the estimated loss arising due to the impairment of value (through diminution, damage, obsolescence, etc.) of raw materials, finished goods, and other inventories owned by the Company, based on appropriate evidence of impairment available at the interim balance sheet date.

Increases or decreases to the provision balance are recorded into the cost of goods sold account in the interim income statement. When inventories are expired, obsolescence, damage or become useless, the difference between the provision previously made and the historical cost of inventories are included in the interim income statement.

### Inventory property

Property acquired or being constructed for sale in the ordinary course of business, rather than to be held for rental or capital appreciation, is held as inventory property and is measured at the lower of cost and NRV.

### NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

### 3.3 Inventories (continued)

Inventory property (continued)

Cost of inventory property comprises:

- Purchase cost, freehold and leasehold rights for land;
- Amounts paid to contractors for construction; and
- Borrowing costs, planning and design costs, costs of site preparation, professional fees for legal services, property transfer taxes, construction overheads and other related costs.

Net realizable value is the estimated selling price in the ordinary course of the business, based on market price discounted for the time value of money if significant at the balance sheet date, and less cost to complete and the estimated selling price.

The cost of the inventory property sold recognized in the interim income statement based on specific identification method.

### 3.4 Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation.

The cost of a tangible fixed asset comprises its purchase price and any directly attributable costs of bringing the tangible fixed asset to working condition for its intended use and the costs of dismantling and removing the asset and restoring the site on which it is located, if any.

Expenditures for additions, improvements and renewals are added to the carrying amount of the assets and expenditures for maintenance and repairs are charged to the interim income statement as incurred.

When tangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the interim income statement.

### 3.5 Intangible fixed assets

Intangible fixed assets are stated at cost less accumulated amortisation.

The cost of an intangible fixed asset comprises its purchase price and any directly attributable costs of preparing the intangible fixed asset for its intended use.

Expenditures for additions, improvements are added to the carrying amount of the assets and other expenditures are charged to the interim income statement as incurred.

When intangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the interim income statement.

### 3.6 Depreciation and amortisation

Depreciation of tangible fixed assets and amortisation of intangible fixed assets are calculated on a straight-line basis over the estimated useful life of each asset as follows:

Buildings and structures	5 - 45 years
Machinery and equipment	5 - 10 years
Waterway transport vehicles	6 - 10 years
Office equipment	3 - 6 years
Computer software	2 - 3 years
Others	3 years

No amortisation is required for infinite land use right.

H

/0 (A

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

### 3.7 Construction in progress

Construction in progress represents the costs of acquiring new assets that have not yet been fully installed or the costs of construction that have not yet been fully completed. Construction in progress is stated at cost, which includes all necessary costs to construct, repair, renovate, expand, or re-equip the projects with technologies, such as construction costs, tools and equipment costs, project management costs, construction consulting costs, and borrowing costs that are eligible for capitalization. Construction in progress will be transferred to the appropriate fixed asset account when these assets are fully installed or the construction project is fully completed, and depreciation of these assets will commence when they are ready for their intended use.

Construction costs are recognized as expenses when such costs do not meet the conditions to be recognized as fixed assets.

### 3.8 Prepaid expenses

Prepaid expenses are reported as short-term or long-term prepaid expenses on the interim balance sheet and amortised over the period for which the amounts are paid or the period in which economic benefits are generated in relation to these expenses.

The prepaid land rental represents the unamortised balance of advance payment made in accordance with the lease contract signed with Northwest Saigon City Development Corporation on 18 December 2018 for a period of 36 years. Such prepaid rental is recognised as a long-term prepaid expense for allocation to the interim income statement over the remaining lease period according to Circular 45.

### 3.9 Investments

Held-to-maturity investments

Held-to-maturity investments are stated at their acquisition costs. After initial recognition, held-to-maturity investments are measured at recoverable amount. Any impairment loss incurred is recognised as finance expense in the interim income statement and deducted against the value of such investments.

### 3.10 Payables and accruals

Payables and accruals are recognised for amounts to be paid in the future for goods and services received, whether or not billed to the Company.

### 3.11 Accrual for severance pay

The severance pay to employee is accrued at the end of each reporting year for employees who have been worked for more than 12 months at the Company. The accrued amount is calculated at the rate of one-half of the average monthly salary for each year of service qualified for severance pay in accordance with the Labor Code and related implementing guidance. The average monthly salary used in this calculation is adjusted at the end of each reporting period following the average monthly salary of the last 6-month period up to the reporting date. Increases or decreases to the accrued amount other than actual payment to employee will be taken to the interim income statement.

This accrued severance pay is used to settle the termination allowance to be paid to employee upon termination of their labor contract following Article 46 of the Labor Code.

I

U

N

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

### 3.12 Foreign currency transactions

Transactions in currencies other than the Company's reporting currency of VND are recorded at the actual transaction exchange rates at transaction dates which are determined as follows:

- Transactions resulting in receivables are recorded at the buying exchange rate of the commercial bank designated for collection; and
- Transactions resulting in liabilities are recorded at the selling exchange rate of the commercial bank designated for payment.

At the end of the period, monetary balances denominated in foreign currencies are translated at the actual exchange rates at interim balance sheet date, determined as follows:

- Monetary assets are translated at the buying exchange rate of the commercial bank where the Company conducts transactions regularly; and
- Monetary liabilities are translated at the selling exchange rate of the commercial bank where the Company conducts transactions regularly.

All foreign exchange differences incurred are taken to the interim income statement.

### 3.13 Contributed capital

Ordinary shares

Ordinary shares are recognised at issuance price less incremental costs directly attributable to the issue of shares, net of tax effects. Such costs are recognised as a deduction from share premium.

Share premium

Share premium is the difference between the par value and the issuance price of the shares, minus the actual expenses incurred for the issuance of the shares.

### 3.14 Earnings per share

Basic earnings per share amounts are calculated by dividing net profit/(loss) after tax for the period attributable to ordinary shareholders of the Company (after adjusting for the bonus and welfare fund) by the weighted average number of ordinary shares outstanding during the period.

Diluted earnings per share amounts are calculated by dividing the net profit after tax attributable to ordinary equity holders of the Company (after adjusting for interest on the convertible preference shares) by the weighted average number of ordinary shares outstanding during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

### 3.15 Appropriation of net profits

Net profit after tax (excluding negative goodwill arising from a bargain purchase) is available for appropriation to shareholders after approval by the General Meeting of Shareholders, and after making appropriation to reserve funds in accordance with the Company's Charter and Vietnam's regulatory requirements.

The Company maintains the following reserve funds which are appropriated from the Company's net profit as proposed by the Board of Directors and subject to approval by shareholders at the annual general meeting.

Investment and development fund

This fund is set aside for use in the Company's expansion of its operation or of in-depth investment.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

### 3.15 Appropriation of net profits (continued)

Bonus and welfare fund

This fund is set aside for the purpose of pecuniary rewarding and encouraging, common benefits and improvement of the employees' benefits, and presented as a liability on the interim balance sheet.

### 3.16 Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable, excluding trade discount, rebate and sales return. The following specific recognition criteria must also be met before revenue is recognised:

Sale of goods

Revenue is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, usually upon the delivery of the goods.

Rendering of services

Where the contract outcome can be reliably measured, revenue is recognised by reference to the stage of completion.

Interest income

Interest is recognized on an accrual basis based on the time and actual interest rate for each period.

### 3.17 Taxation

Current income tax

Current income tax assets and liabilities for the current and prior period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted as at the interim balance sheet date.

Current income tax is charged or credited to the interim income statement, except when it relates to items recognised directly to equity, in which case the current income tax is also dealt with in equity.

Current income tax assets and liabilities are offset when there is a legally enforceable right for the Company to set off current tax assets against current tax liabilities and when the Company intends to settle its current tax assets and liabilities on a net basis.

### Deferred tax

Deferred tax is provided using the liability method on temporary differences at the interim balance sheet date between the tax base of assets and liabilities and their carrying amount for financial reporting purposes.

Deferred tax liabilities are recognised for all taxable temporary differences, except where the deferred tax liability arises from the initial recognition of an asset or liability in a transaction which at the time of the related transaction affects neither the accounting profit nor taxable profit or loss.

Deferred tax assets are recognised for all deductible temporary differences, carried forward unused tax credit and unused tax losses, to the extent that it is probable that taxable profits will be available against which deductible temporary differences, carried forward unused tax credit and unused tax losses can be utilized, except where the deferred tax asset in respect of deductible temporary difference which arises from the initial recognition of an asset or liability which at the time of the related transaction, affects neither the accounting profit nor taxable profit or loss

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

### **3.17 Taxation** (continued)

Deferred tax (continued)

The carrying amount of deferred tax assets is reviewed at each interim balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Previously unrecognised deferred tax assets are re-assessed at each interim balance sheet date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax assets to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realised, or the liability is settled based on tax rates and tax laws that have been enacted at the interim balance sheet date.

Deferred tax is charged or credited to the interim income statement, except when it relates to items recognised directly to equity, in which case the deferred tax is also dealt with in equity account.

Deferred tax assets and liabilities are offset when there is a legally enforceable right for the Company to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority on either the same taxable entity; or when the Company intends either to settle current tax liabilities and assets on a net basis or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

### 3.18 Segment information

A segment is a component determined separately by the Company which is engaged in providing products or related services (business segment) or providing products or services in a particular economic environment (geographical segment), that is subject to risks and returns that are different from those of other segments.

The Company's principal activities are manufacturing pharmaceutical medicine, pharmaceutical chemistry, trading, services and real estates. In addition, these activities are mainly taking place within Vietnam. Therefore, the Company's risks and returns are not impacted by the Company's products that the Company is manufacturing or the locations where the Company is trading. As a result, the Company's management is of the view that there is only one segment for business and geography and therefore presentation of segmental information is not required.

### 3.19 Related parties

Parties are considered to be related parties of the Company if one party has the ability to, directly or indirectly, control the other party or exercise significant influence over the other party in making financial and operating decisions, or when the Company and other party are under common control or under common significant influence. Related parties can be enterprises or individuals, including close members of their families.

W.S.O.S.M. \* 11.

?

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 4. CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTO		
		VND
	30 June 2025	31 December 2024
Cash on hand Cash at banks	10,387,916 2,287,894,244 7,483,302,939	72,000,507 15,809,614,904 12,401,547,049
Cash equivalents (*)	9,781,585,099	28,283,162,460
TOTAL		

<sup>(\*)</sup> Cash equivalents represent deposits in VND with a term of one (1) to three (3) months at commercial banks and earned interest at the rate of 3.0% to 3.4% per annum.

### 5. HELD-TO-MATURITY INVESTMENTS

These are term deposits at commercial banks with original terms of over three (3) months and a remaining term of no more than one year and earn interest at the rate of 4.1% to 5.6% per annum.

### 6. SHORT-TERM TRADE RECEIVABLES

		VND
	30 June 2025	31 December 2024
Trade receivables from customers	21,286,474,122	24,310,509,936
Kim Long House Construction and Trading Company Limited Da Hoang Chuong Pharmacy Company Limited Other customers Trade receivable from a related party (Note 22)  TOTAL	12,825,176,072 1,359,914,922 7,101,383,128 13,034,032,698	7,655,543,722
	34,320,506,820	41,267,169,521
	(17,648,469,382)	
Provision for doubtful receivables	16,672,037,438	23,618,700,139
NET		

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 7. **OTHER RECEIVABLES**

	30 June 2025	VND 31 December 2024
Short-term Receivables of land rentals from Kim Long Construction and Housing Business	4,407,126,000	6,437,509,409
Company Limited Advance to employees Tan Hiep Loi Packaging Production Trading	3,601,800,798 75,278,848	3,601,800,798 120,124,000
Joint Stock Company Others	- 730,046,354	1,995,664,090 719,920,521
Long-term Receivables from Business Cooperation Contract to Kim Long Construction and	3,771,660,200	3,761,660,200
Housing Business Company Limited (*) Deposits	3,636,096,600 135,563,600	3,636,096,600 125,563,600
TOTAL	8,178,786,200	10,199,169,609
Provision for doubtful other receivables	(3,644,234,494)	(3,644,234,494)
NET	4,534,551,706	6,554,935,115

(\*) This receivable represents the value of the house which the Company contributed under the Business Cooperation Contract No. 24/HD/XN25 dated 24 February 2005 ("Contract No. 24") with Kim Long Construction and Housing Business Company Limited to develop Master Building located at No. 41-43 Tran Cao Van, Xuan Hoa Ward, Ho Chi Minh City. As at 30 June 2025, the Company was in the process of transferring its entire rights and obligations arising from Contract No. 24 to An Phat Investment and Trading Joint Stock Company (Note 14.2).

### 8. **BAD DEBTS**

			VND
	30 June 2025 and 31 December 2024		
	Cost	Provision	Recoverable amount
Kim Long Construction and Housing Business Company Limited Khác	20,063,073,470 5,686,641,893	(16,426,976,870) (5,686,641,893)	3,636,096,600
TOTAL	25,749,715,363	(22,113,618,763)	3,636,096,600

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 9. INVENTORIES

				VND
	30 June	e 2025	31 Decem	ber 2024
	Cost	Provision	Cost	Provision
Real estate				
property (*)	160,622,501,912	-	160,622,501,912	-
Raw materials	38,123,020,997	(2,448,766,575)	29,512,724,979	(2,536,270,117)
Finished goods	11,718,013,183	-	9,958,599,769	-
Work in process	1,645,936,201	=	1,640,958,292	=
Tools and supplies	21,468,000	=	22,024,800	-
Merchandise				
goods			11,242,000	<u>_</u>
TOTAL	212,130,940,293	(2,448,766,575)	201,768,051,752	(2,536,270,117)

<sup>(\*)</sup> This represents the leasehold right for land located No. 120 Hai Ba Trung, Sai Gon Ward, Ho Chi Minh City granted to the Company, in relation to the agreement between the Company and Tay Ninh Industrial Park Infrastructure Development Joint Stock Company (Note 14.2).

Detail of movements of provision for obsolete inventories are as follows:

		VND
	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
Beginning balance Provision made during the period Reversal during the period	2,536,270,117 - (87,503,542)	2,051,821,321 302,669,826 (641,372,882)
Ending balance	2,448,766,575	1,713,118,265

### 10. STATUTORY OBLIGATIONS

TOTAL	423,682,688	5,971,899,224	(5,828,178,465)	567,403,447
Value-added tax on imported goods	208,560,300	1,132,504,415	(1,341,064,715)	
land lease fees Personal income tax	- 68,857,130	2,009,206,378 595,554,960	(1,918,113,574) (585,707,474)	91,092,804 78,704,616
Value-added tax Land tax and	146,265,258	2,234,633,471	(1,983,292,702)	397,606,027
	31 December 2024	Increase in period	Decrease in period	30 June 2025

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 11. TANGIBLE FIXED ASSETS

					QNA
	Buildings and structures	Machinery and equipment	Means of transportation	Office equipment	Total
Cost:					
As at 31 December 2024 and 30 June 2025	38,973,526,498	67,179,897,456	2,713,306,813	762,363,930	109,629,094,697
In which: Fully depreciated	4,513,091,128	54,871,901,441	2,081,615,904	762, 363, 930	62,228,972,403
Accumulated depreciation:					
As at 31 December 2024 Depreciation for the period	23,787,615,154 435,660,852	62,586,047,716 716,449,576	2,607,139,074 45,120,780	762,363,930	89,743,165,874 1,197,231,208
As at 30 June 2025	24,223,276,006	63,302,497,292	2,652,259,854	762,363,930	90,940,397,082
Net carrying amount:					
As at 31 December 2024	15,185,911,344	4,593,849,740	106,167,739	t	19,885,928,823
As at 30 June 2025	14,750,250,492	3,877,400,164	61,046,959	1	18,688,697,615

= ( N 1 O N 1 !! =

12/1

H YI U

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended  $\,$ 

### 12. CONSTRUCTION IN PROGRESS

The balance represents the costs incurred for the purpose of building a factory at Tan Phu Trung Industrial Park, Tram Bom Hamlet, Cu Chi Commune, Ho Chi Minh City.

### 13. PREPAID EXPENSES

		VND
	30 June 2025	31 December 2024
Infrastructure rental fee (*) Others	47,758,831,087 93,100,000	48,562,134,538
TOTAL	47,851,931,087	48,562,134,538

(\*) This amount represents the prepaid infrastructure rental fees arising from the land lease contract No.109/HDTD/SCD-2018 dated 12 October 2018 between the Company and Northwest Saigon Urban Development Joint Stock Company ("SCD") to lease infrastructure at Lot B5-4, Zone B5, Road D2, Tan Phu Trung Industrial Park, Tram Bom Hamlet, Cu Chi Commune, Ho Chi Minh City with an area of 30,866 m² for the contruction of the factory. The lease term is from 10 January 2020 to 16 December 2054.

### 14. TRADE PAYABLES AND ADVANCES FROM CUSTOMERS

### 14.1 Trade payables

	30 June 2025	VND 31 December 2024
Trade payables to suppliers  Benovas Pharmaceutical JSC  Multipack Co., Ltd	2,030,100,028 604,047,456 296,949,888	14,035,264,452 1,813,699,620 599,584,291
Dang Hung Chemical Co., Ltd Sinobright Pharmaceutical Co, Ltd. Viet Uy JSC	246,330,000	4,225,113,360 1,921,500,000
Others Trade payable to a related party (Note 22)  TOTAL	882,772,684 46,462,500 <b>2,076,562,528</b>	5,475,367,181 46,462,500 14,081,726,952

77

GI

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 14. TRADE PAYABLES AND ADVANCES FROM CUSTOMERS (continued)

### 14.2 Advances from customers

	30 June 2025	VND 31 December 2024
Tay Ninh Industrial Park Infrastructure Development Joint Stock Company (i) An Phat Business Trading Investment	178,082,838,961	178,082,838,961
Joint Stock Company (ii) Others	5,000,000,000 5,626,435	5,000,000,000 3,116,516
TOTAL	183,088,465,396	183,085,955,477

- (i) This represents the advance received from Tay Ninh Industrial Park Infrastructure Development Joint Stock Company ("INDECO") in pursuant to the Cooperation, Investment, and Properties Transfer Contract No. 58/TW25-INDECO dated 27 August 2018 between the Company and INDECO to invest in the construction of an Office Building located at No. 120 Hai Ba Trung, Sai Gon Ward, Ho Chi Minh City. In addition, on 11 September 2018, the Company and INDECO also signed a contract in relation to the designing, supplying technological equipment and construction works ("EPC") No. 59/TW25-INDECO for the Office Building project on this land lot. Accordingly, all works, procedures and costs related to the construction and completion of the building will be carried out and born by INDECO. As at 30 June 2025, this project is currently in the process of finalizing the technical design appraisal documents and applying for the construction permit.
- (ii) This represents the advance received from An Phat Investment Trading Business Joint Stock Company ("An Phat") under the Contract No. 20/2018/HĐCN/TW25-AP regarding the transfer of the Company's rights and obligations from the Business Cooperation Contract No. 24/HĐ/XN25 dated 24 February 2005, with Kim Long Construction and Housing Business Company Limited and the right to lease the land at No 41-43 Tran Cao Van, Xuan Hoa Ward, Ho Chi Minh City. As at 30 June 2025, the transfer procedure has not been completed yet.

B09a-DN

LATE

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 15. OTHER SHORT-TERM PAYABLES

		VND
	30 June 2025	31 December 2024
Southern Public Interest Environmental		
Corporation (*)	26,250,000,000	26,250,000,000
Deposits	420,000,000	420,000,000
Social Insurance	224,338,249	-
Trade Union	220,362,348	225,233,841
Dividend	221,634,744	221,634,744
Others	693,618,440	519,202,876
TOTAL	28,029,953,781	27,636,071,461

(\*) This is the amount received from Southern Public Interest Environmental Corporation ("SPEC") in pursuant to the Transfer Contract No. 68/2017/HDCN/SPEC/TW-25 dated 2 November 2017 between the Company and SPEC to transfer the assets attached to the leasehold land and the right to exploit and develop the project on this land located at No. 448B Nguyen Tat Thanh, Xom Chieu Ward, Ho Chi Minh City with a total contract value of VND 75,000,000,000. In accordance with Resolution No. 58/NQ-HDQT-TW25 dated 12 August 2022, the Board of Directors approved the liquidation of the Transfer Contract. As at 30 June 2025, the Company is in the process to negotiate with SPEC to proceed with necessary procedures to liquidate the contract.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 16. OWNERS' EQUITY

## 16.1 Increase and decrease in owners' equity

					QNA
	Share capital	Share premium	Investment and development fund	Undistributed earnings	Total
For the six-month period ended 30 June 2024:	0 June 2024:				
As at 31 December 2023 Net profit for the period	132,946,410,000	17,589,282,000	12,490,339,501	(10,944,239,776) 1,512,775,281	152,081,791,725 1,512,775,281
As at 30 June 2024	132,946,410,000	17,589,282,000	12,490,339,501	(9,431,464,495)	153,594,567,006
For the six-month period ended 30 June 2025:	0 June 2025:				
As at 31 December 2024 Net profit for the period	132,946,410,000	17,589,282,000	12,490,339,501	(7,873,926,329) 178,776,772	155,152,105,172 178,776,772
As at 30 June 2025	132,946,410,000	17,589,282,000	12,490,339,501	(7,695,149,557)	155,330,881,944

181 7 A E Z

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 16. OWNERS' EQUITY (continued)

### 16.2 Contributed charter capital

	30 June 202	5 and 31 December	2024
•	Number of ordinary shares	Amount (VND)	Ownership %
OPC Pharmaceutical Joint Stock Company Vietnam Pharmaceutical Corporation Others	7,730,000 3,780,000 1,784,641	77,300,000,000 37,800,000,000 17,846,410,000	58.14 28.43 13.43
TOTAL	13,294,641	132,946,410,000	100.00

### 16.3 Share capital

	Qua	ntity
	30 June 2025	31 December 2024
Authorized shares	13,294,641	13,294,641
Shares issued and fully paid	13,294,641	13,294,641
Shares in circulation	13,294,641	13,294,641

The Company's shares are issued with par value of VND 10,000 per share.

### 16.4 Earnings per share

The following reflects the income and share data used in the basic and diluted earnings per share computations:

	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
Net profit after tax allocated to shareholders owning common shares (VND)	178,776,772	1,512,775,281
Net profit after tax is allocated to shareholders owning common shares to calculate the above basic interest (VND)	178,776,772	1,512,775,281
The average number of ordinary shares circulated (shares)	13,294,641	13,294,641
Earnings per share Basic earnings per share (VND per share) Diluted earnings per share (VND per share)	13 13	114 114

There have been no dilutive potential ordinary shares during the year and up to the date of these interim financial statements.



NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 17. REVENUES

### 17.1 Revenue from sale of goods and rendering of services

	Nevertue from oute of goods and condeming of		
			VND
		For the six-month	For the six-month
		period ended	period ended
		30 June 2025	, 30 June 2024
	Gross revenue	39,369,353,164	59,489,687,151
	In which:		
	Sales of finished goods, merchandise	38,349,288,792	58,424,453,011
	Sales of rendering the services	1,020,064,372	1,065,234,140
	Lana	_	(157,457)
	Less	-	(157,457)
	Sales returns		
	TOTAL	39,369,353,164	59,489,529,694
	In which:		
	Sales to related parties (Note 22)	35,393,421,698	46,873,854,964
	Sales to others	3,975,931,466	12,615,674,730
17.2	Finance income		
			VND
		For the six-month	For the six-month
		period ended	period ended
		30 June 2025	30 June 2024
	Interest income	1,178,932,701	1,002,395,397
	Foreign exchange gains	170,961,367	53,102,318
	TOTAL	1,349,894,068	1,055,497,715
18.	COST OF GOODS SOLD AND SERVICES REND	DERED	
			VND
		For the six-month	
		period ended	For the six-month period ended
		30 June 2025	30 June 2024
		***********	
	Cost of finished goods and merchandise sold	34,260,701,956	50,266,209,074
	Cost of limished goods and merchandise sold	551,608,532	810,197,655
	TOTAL	34,812,310,488	51,076,406,729

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 19. SELLING EXPENSES AND GENERAL AND ADMINISTRATIVE EXPENSES

		VND
	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
Selling expenses	404,335,569	761,493,111
Labour cost	311,804,076	608,011,049
Depreciation expenses	25,218,180	25,218,180
Others	67,313,313	128,263,882
General and administrative expenses	5,188,720,612	7,162,325,342
Labour cost	2,288,181,889	3,263,979,940
External services	476,164,000	161,666,377
Depreciation expenses	44,162,076	45,208,445
Others	2,380,212,647	3,691,470,580
TOTAL	5,593,056,181	7,923,818,453

### 20. PRODUCTION AND OPERATING COSTS

TOTAL	41,617,999,835	58,663,848,127
Raw materials Labour cost Expenses for external services Depreciation expenses Others	26,574,420,753 7,640,916,740 1,866,847,948 1,179,549,388 4,356,265,006	37,224,919,462 10,976,834,041 1,979,377,282 1,393,584,697 7,089,132,645
	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024

### 21. CORPORATE INCOME TAX

The statutory corporate income tax ("CIT") rate applicable to the Company is 20% of taxable income.

The tax returns filed by the Company are subject to examination by the tax authorities. As the application of tax laws and regulations is susceptible to varying interpretations, the amounts reported in the interim financial statements could change at a later date upon final determination by the tax authorities.

NI & T

### No. 25 Central Pharmaceutical Joint Stock Company

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 21. CORPORATE INCOME TAX (continued)

### 21.1 CIT expense

		VND
	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
Current tax expense	-	1,287,000
Deferred tax expense	105,769,193	1,207,000
	105,769,193	1,287,000
TOTAL		

Reconciliation between CIT expense and the accounting profit before tax multiplied by CIT rate is presented below:

	For the six-month period ended 30 June 2025	VND For the six-month period ended 30 June 2024
a musting mustit before tay	284,545,965	1,514,062,281
Accounting profit before tax	56,909,193	302,812,456
At CIT rate of 20% applicable to the Company	56,909,195	002,012,100
Adjustment of tax expense due to  Non-deductible expenses	48,860,000	73,945,209
Tax losses available for offset against future	105,769,193	=
taxable income (Note 21.3)	(105,769,193)	(375,470,665)
Tax loss carried forward	105,769,193	1,287,000
CIT expense		

### 21.2 Current CIT

The current tax payable is based on taxable income for the period. The taxable income of the Company for the period differs from the profit as reported in the interim income statement because it excludes items of income or expense that are taxable or deductible in other periods and it further excludes items that are not taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted at the interim balance sheet date.

1

Y

N

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 21. CORPORATE INCOME TAX (continued)

### 21.3 Deferred tax

The following are the deferred tax assets recognised by the Company, and the movements thereon, during the current and previous period:

				VND
	Balance	sheet	Income s	tatement
-	30 June 2025	31 December 2024	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
Tax losses available for offset against future				
taxable income (Note 21.4)	359,563,626	465,332,819	(105,769,193)	-
Severance allowance	191,999,500	191,999,500	-	(1,287,000)
Net deferred tax assets	551,563,126	657,332,319		
Net deferred tax ex	penses		(105,769,193)	(1,287,000)

### 21.4 Tax losses carried forward

The Company is entitled to carry tax loss forward to offset against taxable income arising within five years subsequent to the year in which the loss was incurred. At the interim balance sheet date, the Company has aggregated accumulated tax losses of VND 1,797,818,132 (31 December 2024: VND 2,326,664,097) available for offset against future taxable income. Details are as follows:

Originating year	Can be utilized up to	Tax loss amount	Utilized up to 30 June 2025	VND Unutilized at 30 June 2025
2019 2020 (*) 2021 (*)	2024 2025 2026	2,732,196,644 4,139,979,647 3,788,041,767	(2,732,196,644) (4,139,979,647) (1,990,223,635)	1,797,818,132
TOTAL		10,660,218,058	(8,862,399,926)	1,797,818,132

<sup>(\*)</sup> Tax loss is adjusted according to Decision No. 549/QD-CT dated 29 March 2023 issued by Ho Chi Minh City Tax Department.

B09a-DN

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### TRANSACTIONS WITH RELATED PARTIES 22.

List of related parties that have a controlling relationship with the Company during the period and as at 30 June 2025 is as follows:

Related parti-	es
----------------	----

Co., Ltd.

Relationship

Kelatoa partie	
OPC Pharmaceutical Joint Stock Company OPC Binh Duong Pharmaceutical One Member Co., Ltd. Ms Pham Thi Xuan Huong Ms Phuong Thanh Nhung Mr Tran Tri Duc Mr Ha Duc Cuong Ms Ha Lan Anh Mr Nguyen Manh Hai Mr Ngo Tan Long	Parent company Common ownership by ultimate parent company Chairwoman Member of the Board of the Directors Deputy General Director

Transactions with related parties during the period were as follows:

Transactions with related parties du	ing the penea man		VND
	Transactions	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
Related parties			
OPC Pharmaceutical Joint Stock Company	Sale of goods Sale of others Purchase of goods Return of goods	35,351,421,698 42,000,000 609,000	46,832,012,421 42,000,000 1,139,250 157,457
OPC Binh Duong Pharmaceutica One Member Co., Ltd.		177,000,000	
Offe Member 334	used parties at the	e interim balance s	heet dates were as
One Member Co., Ltd.  Amounts due to and due from r	elated parties at the		
follows:			VND
Related parties	Transactions	30 June 30 202	
Short-term trade receivable (NOPC Pharmaceutical Joint Stoce Company	<i>Note 6)</i> <sub>k</sub> Sale of good	s <u>13,034,032,69</u>	16,956,659,585
Short-term trade payable (No	te 14.1)	of	500
OPC Binh Duong Pharmaceutical One Member	Purchase good		00 46,462,500

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### TRANSACTIONS WITH RELATED PARTIES (continued) 22.

Remuneration of members of the Board of Directors, the management and the Board of Supervision including salary, bonus and other benefits was as follows: VND

		VND
Position	For the six-month period ended 30 June 2025	For the six-month period ended 30 June 2024
	135,000,000	135,000,000
Chainyoman		39,000,000
	24,000,000	24,000,000
	24,000,000	24,000,000
	24,000,000	24,000,000
	24,000,000	
	-	16,000,000
	60,000,000	60,000,000
Head	* * * * * * * * * * * * * * * * * * * *	
	000	18,000,000
		18,000,000
		_ 16,000,000
		3 886,753,339
Coneral Directo	00 00	
	al	314,180,000
Directo	or 290,881,85	57 314, 180,000
Former Gener	al or	492,573,339
Direct		23 1,081,753,339
	•	
	Position  Chairwoman Member Member Member Former Member Head Member Member General Director Deputy General Former General	Position         June 2025           135,000,000         39,000,000           Member         24,000,000           Member         24,000,000           Member         24,000,000           Member         24,000,000

B09a-DN

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continued) as at 30 June 2025 and for the six-month period then ended

### 23. COMMITMENTS

### Operating lease commitment

The Company leases under operating lease arrangements. The minimum lease commitments as at the interim balance sheet dates under the operating lease agreements are as follows:

**VND** 

30 June 2025 31 December 2024

Less than 1 year

2,423,647,250

1,201,734,194

### Commitment relating to significant investment costs

As at 30 June 2025, the Company has a commitment amounting to VND 12,525,700,000 (as at 31 December 2024: VND 12,525,700,000), primarily related to the construction of a factory.

### 24. OFF BALANCE SHEET ITEMS

30 June 2025 31 December 2024

Foreign currency:

United States dollar (USD)

9,834.59

387.45

### 25. EVENTS AFTER THE INTERIM BALANCE SHEET DATE

There is no significant matter or circumstance that has arisen since the interim balance sheet date that requires adjustment or disclosure to be made in the interim financial statements of the Company.

Ngo Tan Long

Preparer cum Deputy General Director

Ho Chi Minh City, Vietnam

14 August 2025

Nguyen Manh Hai

General Director

\*

### EY | Building a better working world

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, Al and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

© 2025 Ernst & Young Vietnam Limited. All Rights Reserved.

ey.com/en\_vn